Susan Ingram
Concepts (324)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Periaqueductal Gray | 30 | 2025 | 37 | 6.300 |
Why?
| | Receptors, Opioid, mu | 15 | 2025 | 68 | 3.650 |
Why?
| | Analgesics, Opioid | 29 | 2025 | 1143 | 3.340 |
Why?
| | gamma-Aminobutyric Acid | 12 | 2025 | 192 | 3.060 |
Why?
| | Morphine | 21 | 2022 | 168 | 3.010 |
Why?
| | Pain | 17 | 2025 | 779 | 2.690 |
Why?
| | Drug Tolerance | 21 | 2021 | 100 | 2.640 |
Why?
| | Presynaptic Terminals | 5 | 2022 | 86 | 1.530 |
Why?
| | Rats, Sprague-Dawley | 33 | 2025 | 2527 | 1.320 |
Why?
| | Methamphetamine | 3 | 2025 | 70 | 1.320 |
Why?
| | Neurons | 21 | 2022 | 1640 | 1.310 |
Why?
| | Cannabinoids | 3 | 2023 | 182 | 1.290 |
Why?
| | Endocannabinoids | 4 | 2025 | 57 | 1.280 |
Why?
| | Receptor, Cannabinoid, CB1 | 3 | 2025 | 39 | 1.240 |
Why?
| | Receptors, Opioid | 4 | 2022 | 23 | 1.220 |
Why?
| | Analgesics | 8 | 2022 | 228 | 1.190 |
Why?
| | Medulla Oblongata | 4 | 2017 | 37 | 1.090 |
Why?
| | Opioid Peptides | 6 | 2020 | 9 | 1.010 |
Why?
| | Central Nervous System Stimulants | 3 | 2025 | 185 | 0.950 |
Why?
| | Rats | 30 | 2025 | 5597 | 0.950 |
Why?
| | Glycerides | 1 | 2025 | 17 | 0.910 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 3 | 2018 | 10 | 0.900 |
Why?
| | Arachidonic Acids | 1 | 2025 | 43 | 0.890 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2025 | 233 | 0.880 |
Why?
| | Dorsal Raphe Nucleus | 1 | 2025 | 31 | 0.870 |
Why?
| | Serotonergic Neurons | 1 | 2025 | 29 | 0.870 |
Why?
| | Animals | 59 | 2025 | 38058 | 0.840 |
Why?
| | RGS Proteins | 3 | 2021 | 17 | 0.840 |
Why?
| | Corticosterone | 1 | 2025 | 244 | 0.830 |
Why?
| | Receptors, Glucocorticoid | 1 | 2025 | 138 | 0.810 |
Why?
| | GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2021 | 19 | 0.780 |
Why?
| | Amphetamine | 3 | 2019 | 38 | 0.760 |
Why?
| | Hyperalgesia | 2 | 2021 | 131 | 0.740 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2016 | 226 | 0.740 |
Why?
| | GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2021 | 5 | 0.690 |
Why?
| | Pain Measurement | 17 | 2019 | 552 | 0.690 |
Why?
| | Pain Threshold | 4 | 2019 | 73 | 0.680 |
Why?
| | Mesencephalon | 2 | 2016 | 64 | 0.680 |
Why?
| | Synaptic Transmission | 7 | 2024 | 290 | 0.640 |
Why?
| | Pyramidal Tracts | 1 | 2020 | 30 | 0.610 |
Why?
| | Dopaminergic Neurons | 3 | 2019 | 67 | 0.610 |
Why?
| | Inhibitory Postsynaptic Potentials | 4 | 2021 | 48 | 0.610 |
Why?
| | Narcotics | 5 | 2006 | 55 | 0.550 |
Why?
| | Receptors, GABA-A | 2 | 2016 | 138 | 0.520 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2017 | 11 | 0.510 |
Why?
| | Synaptic Potentials | 1 | 2016 | 17 | 0.500 |
Why?
| | Nerve Net | 1 | 2020 | 285 | 0.490 |
Why?
| | Microinjections | 11 | 2013 | 92 | 0.480 |
Why?
| | Societies, Scientific | 3 | 2020 | 49 | 0.480 |
Why?
| | Adenylyl Cyclases | 3 | 2014 | 60 | 0.470 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2016 | 2027 | 0.470 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 8 | 2022 | 11 | 0.420 |
Why?
| | Corydalis | 1 | 2014 | 1 | 0.420 |
Why?
| | Medicine, Chinese Traditional | 1 | 2014 | 8 | 0.420 |
Why?
| | Alkaloids | 1 | 2014 | 28 | 0.410 |
Why?
| | Male | 39 | 2025 | 72315 | 0.410 |
Why?
| | Adrenergic Neurons | 2 | 2024 | 7 | 0.410 |
Why?
| | Chronic Pain | 2 | 2016 | 290 | 0.410 |
Why?
| | Inflammation | 6 | 2025 | 2878 | 0.410 |
Why?
| | Glutamic Acid | 3 | 2018 | 251 | 0.400 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 173 | 0.400 |
Why?
| | Dopamine | 5 | 2019 | 283 | 0.380 |
Why?
| | Action Potentials | 8 | 2024 | 506 | 0.380 |
Why?
| | Mice, Transgenic | 4 | 2025 | 2182 | 0.380 |
Why?
| | Baclofen | 4 | 2021 | 21 | 0.380 |
Why?
| | Brain | 3 | 2025 | 2933 | 0.360 |
Why?
| | Receptor Aggregation | 1 | 2012 | 10 | 0.360 |
Why?
| | Mice | 13 | 2025 | 18339 | 0.360 |
Why?
| | Signal Transduction | 6 | 2023 | 5226 | 0.360 |
Why?
| | Membrane Transport Proteins | 3 | 2002 | 154 | 0.360 |
Why?
| | Pain Perception | 3 | 2020 | 24 | 0.320 |
Why?
| | Sex Characteristics | 1 | 2016 | 790 | 0.320 |
Why?
| | Receptors, GABA-B | 2 | 2021 | 10 | 0.320 |
Why?
| | Receptors, Glutamate | 1 | 2009 | 26 | 0.300 |
Why?
| | Nerve Tissue Proteins | 3 | 2002 | 592 | 0.300 |
Why?
| | Receptors, Dopamine | 1 | 2009 | 19 | 0.290 |
Why?
| | Membrane Glycoproteins | 3 | 2002 | 496 | 0.290 |
Why?
| | Research Personnel | 2 | 2020 | 186 | 0.280 |
Why?
| | Protein Kinase C | 1 | 2009 | 252 | 0.270 |
Why?
| | Morphine Dependence | 1 | 2007 | 3 | 0.270 |
Why?
| | Hot Temperature | 4 | 2016 | 407 | 0.260 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5992 | 0.250 |
Why?
| | Nociception | 2 | 2019 | 17 | 0.250 |
Why?
| | Electrophysiology | 3 | 2006 | 218 | 0.250 |
Why?
| | Nociceptive Pain | 2 | 2017 | 4 | 0.250 |
Why?
| | Locomotion | 2 | 2018 | 105 | 0.250 |
Why?
| | Excitatory Amino Acid Transporter 3 | 2 | 2018 | 4 | 0.250 |
Why?
| | Fentanyl | 3 | 2019 | 127 | 0.240 |
Why?
| | Sympathetic Nervous System | 2 | 2024 | 178 | 0.240 |
Why?
| | Excitatory Amino Acid Antagonists | 5 | 2016 | 107 | 0.240 |
Why?
| | Patch-Clamp Techniques | 7 | 2017 | 289 | 0.230 |
Why?
| | Enkephalin, Methionine | 6 | 2010 | 7 | 0.230 |
Why?
| | GABA Agonists | 4 | 2016 | 24 | 0.230 |
Why?
| | Neurotransmitter Agents | 2 | 2022 | 82 | 0.220 |
Why?
| | Association Learning | 1 | 2005 | 71 | 0.220 |
Why?
| | Oxylipins | 1 | 2025 | 47 | 0.220 |
Why?
| | Aging | 2 | 2018 | 1966 | 0.220 |
Why?
| | Behavior, Animal | 3 | 2009 | 519 | 0.220 |
Why?
| | Ion Channels | 2 | 1996 | 129 | 0.210 |
Why?
| | Stellate Ganglion | 1 | 2024 | 6 | 0.210 |
Why?
| | Adenylyl Cyclase Inhibitors | 2 | 2014 | 7 | 0.210 |
Why?
| | Cholinergic Neurons | 1 | 2024 | 18 | 0.210 |
Why?
| | Drug Interactions | 6 | 2012 | 398 | 0.210 |
Why?
| | Monoacylglycerol Lipases | 1 | 2023 | 5 | 0.200 |
Why?
| | Receptors, Cannabinoid | 1 | 2023 | 14 | 0.200 |
Why?
| | Cell Membrane | 3 | 2025 | 706 | 0.190 |
Why?
| | Naltrexone | 5 | 2013 | 117 | 0.190 |
Why?
| | Reaction Time | 6 | 2013 | 438 | 0.190 |
Why?
| | GABAergic Neurons | 1 | 2023 | 35 | 0.190 |
Why?
| | Cultural Diversity | 2 | 2020 | 87 | 0.190 |
Why?
| | Reward | 1 | 2025 | 247 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2015 | 138 | 0.180 |
Why?
| | Narcotic Antagonists | 5 | 2021 | 205 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2015 | 175 | 0.180 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2016 | 117 | 0.180 |
Why?
| | Allosteric Regulation | 1 | 2021 | 98 | 0.170 |
Why?
| | Locus Coeruleus | 2 | 1998 | 24 | 0.170 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 4 | 2009 | 59 | 0.170 |
Why?
| | Colforsin | 3 | 2014 | 48 | 0.160 |
Why?
| | Arachidonic Acid | 2 | 2000 | 101 | 0.160 |
Why?
| | Chromogranins | 1 | 2019 | 13 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2019 | 9 | 0.150 |
Why?
| | GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2019 | 8 | 0.150 |
Why?
| | Dynamins | 3 | 2014 | 36 | 0.150 |
Why?
| | Pain Management | 2 | 2021 | 405 | 0.150 |
Why?
| | Models, Animal | 1 | 2021 | 392 | 0.150 |
Why?
| | Awards and Prizes | 1 | 2020 | 70 | 0.150 |
Why?
| | Humans | 20 | 2025 | 144759 | 0.150 |
Why?
| | GABA-B Receptor Agonists | 1 | 2018 | 5 | 0.140 |
Why?
| | Amygdala | 1 | 2020 | 198 | 0.140 |
Why?
| | Dinoprostone | 2 | 1996 | 178 | 0.140 |
Why?
| | Cyclic AMP | 2 | 1996 | 209 | 0.140 |
Why?
| | Efferent Pathways | 2 | 2012 | 19 | 0.140 |
Why?
| | Cocaine | 1 | 2000 | 160 | 0.130 |
Why?
| | Parabrachial Nucleus | 1 | 2017 | 3 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.130 |
Why?
| | Second Messenger Systems | 2 | 1997 | 31 | 0.130 |
Why?
| | Benzoxazines | 1 | 2017 | 31 | 0.130 |
Why?
| | Bicuculline | 2 | 2014 | 18 | 0.130 |
Why?
| | GABA-A Receptor Antagonists | 2 | 2014 | 19 | 0.120 |
Why?
| | Female | 10 | 2025 | 78271 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2002 | 737 | 0.120 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 154 | 0.120 |
Why?
| | Naphthalenes | 1 | 2017 | 56 | 0.120 |
Why?
| | Thionucleotides | 1 | 1996 | 35 | 0.120 |
Why?
| | Calcium | 2 | 2000 | 1183 | 0.120 |
Why?
| | Morpholines | 1 | 2017 | 128 | 0.120 |
Why?
| | Nucleotides, Cyclic | 1 | 1996 | 22 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1169 | 0.120 |
Why?
| | Neurons, Afferent | 1 | 1996 | 102 | 0.110 |
Why?
| | Hypertension | 1 | 2024 | 1263 | 0.110 |
Why?
| | Analgesia | 2 | 2021 | 105 | 0.110 |
Why?
| | Analysis of Variance | 4 | 2012 | 1306 | 0.110 |
Why?
| | Endorphins | 1 | 1994 | 9 | 0.110 |
Why?
| | Miniature Postsynaptic Potentials | 1 | 2014 | 10 | 0.110 |
Why?
| | Enzyme Activators | 1 | 2014 | 9 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 824 | 0.100 |
Why?
| | Organic Chemicals | 1 | 2014 | 127 | 0.100 |
Why?
| | Endocytosis | 1 | 2014 | 168 | 0.100 |
Why?
| | Potassium Channels | 3 | 1998 | 145 | 0.100 |
Why?
| | GABA Antagonists | 3 | 2013 | 34 | 0.090 |
Why?
| | Catecholamines | 1 | 2012 | 87 | 0.090 |
Why?
| | In Vitro Techniques | 6 | 2004 | 1047 | 0.090 |
Why?
| | Adenine | 1 | 2014 | 339 | 0.090 |
Why?
| | Dopamine Antagonists | 2 | 2009 | 25 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 1998 | 600 | 0.080 |
Why?
| | Electrophysiological Phenomena | 1 | 2010 | 60 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1716 | 0.080 |
Why?
| | Naloxone | 2 | 2013 | 132 | 0.080 |
Why?
| | Kynurenic Acid | 1 | 2009 | 18 | 0.080 |
Why?
| | Dizocilpine Maleate | 1 | 2009 | 24 | 0.080 |
Why?
| | Flupenthixol | 1 | 2009 | 2 | 0.070 |
Why?
| | Apomorphine | 1 | 2009 | 6 | 0.070 |
Why?
| | Receptors, Opioid, delta | 1 | 2009 | 10 | 0.070 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2009 | 71 | 0.070 |
Why?
| | Dopamine Agonists | 1 | 2009 | 42 | 0.070 |
Why?
| | Staining and Labeling | 1 | 2009 | 151 | 0.070 |
Why?
| | Nerve Fibers | 1 | 2009 | 104 | 0.070 |
Why?
| | Clonidine | 2 | 1998 | 33 | 0.070 |
Why?
| | Age Factors | 3 | 2018 | 3333 | 0.070 |
Why?
| | Dimethyl Sulfoxide | 1 | 2008 | 41 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 321 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 766 | 0.070 |
Why?
| | Brain Chemistry | 1 | 2007 | 116 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2002 | 4154 | 0.060 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 1998 | 125 | 0.060 |
Why?
| | Enkephalins | 2 | 1997 | 21 | 0.060 |
Why?
| | Nodose Ganglion | 2 | 1996 | 5 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2023 | 3121 | 0.060 |
Why?
| | Guinea Pigs | 2 | 1996 | 159 | 0.060 |
Why?
| | Somatostatin | 1 | 2004 | 51 | 0.050 |
Why?
| | Angiotensin II | 1 | 2024 | 97 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 779 | 0.050 |
Why?
| | Ganglia, Sympathetic | 1 | 2023 | 14 | 0.050 |
Why?
| | Cholinergic Agents | 1 | 2023 | 18 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2022 | 30 | 0.050 |
Why?
| | Cytoskeletal Proteins | 1 | 2002 | 156 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2021 | 86 | 0.040 |
Why?
| | Cricetulus | 1 | 2021 | 118 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.040 |
Why?
| | CHO Cells | 1 | 2021 | 171 | 0.040 |
Why?
| | Synapses | 2 | 2002 | 439 | 0.040 |
Why?
| | Evoked Potentials | 2 | 1998 | 128 | 0.040 |
Why?
| | Engineering | 1 | 2020 | 30 | 0.040 |
Why?
| | Posterior Horn Cells | 1 | 2000 | 10 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1732 | 0.040 |
Why?
| | Potassium Chloride | 1 | 2000 | 40 | 0.040 |
Why?
| | N-Methylaspartate | 1 | 2000 | 43 | 0.040 |
Why?
| | Speech | 1 | 2020 | 77 | 0.040 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2000 | 52 | 0.040 |
Why?
| | Xenopus laevis | 1 | 2000 | 105 | 0.040 |
Why?
| | Demography | 1 | 2020 | 288 | 0.040 |
Why?
| | Oligopeptides | 2 | 2013 | 269 | 0.040 |
Why?
| | Travel | 1 | 2020 | 136 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2000 | 141 | 0.040 |
Why?
| | Elapid Venoms | 1 | 1998 | 13 | 0.040 |
Why?
| | Membrane Potentials | 1 | 2000 | 280 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1998 | 27 | 0.040 |
Why?
| | Neurotoxins | 1 | 1998 | 28 | 0.040 |
Why?
| | Oocytes | 1 | 2000 | 178 | 0.040 |
Why?
| | 4-Aminopyridine | 1 | 1998 | 30 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 417 | 0.040 |
Why?
| | Amino Acid Transport System X-AG | 1 | 2018 | 5 | 0.040 |
Why?
| | Excitatory Amino Acid Transporter 1 | 1 | 2018 | 6 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2000 | 178 | 0.040 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2018 | 15 | 0.040 |
Why?
| | Environment | 1 | 2020 | 305 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 237 | 0.030 |
Why?
| | Mentors | 1 | 2020 | 219 | 0.030 |
Why?
| | Enkephalin, Leucine | 1 | 1997 | 3 | 0.030 |
Why?
| | Etorphine | 1 | 1997 | 2 | 0.030 |
Why?
| | Brimonidine Tartrate | 1 | 1997 | 10 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2061 | 0.030 |
Why?
| | Synaptic Membranes | 1 | 1997 | 16 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2017 | 83 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2000 | 309 | 0.030 |
Why?
| | Quinoxalines | 1 | 1997 | 65 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4557 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 338 | 0.030 |
Why?
| | Long-Term Potentiation | 1 | 1998 | 200 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1370 | 0.030 |
Why?
| | Dibutyryl Cyclic GMP | 1 | 1996 | 2 | 0.030 |
Why?
| | Calcium Channels | 1 | 1997 | 154 | 0.030 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 20 | 0.030 |
Why?
| | Capsaicin | 1 | 1996 | 30 | 0.030 |
Why?
| | Trigeminal Ganglion | 1 | 1996 | 26 | 0.030 |
Why?
| | Cyclic GMP | 1 | 1996 | 92 | 0.030 |
Why?
| | Optogenetics | 1 | 2017 | 109 | 0.030 |
Why?
| | Butadienes | 1 | 2015 | 37 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 1996 | 88 | 0.030 |
Why?
| | Neural Pathways | 1 | 2017 | 311 | 0.030 |
Why?
| | Adenosine Monophosphate | 1 | 1996 | 86 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1499 | 0.030 |
Why?
| | Students | 1 | 2020 | 663 | 0.030 |
Why?
| | Electric Conductivity | 1 | 1994 | 84 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 205 | 0.030 |
Why?
| | Adenosine | 1 | 1996 | 255 | 0.030 |
Why?
| | Cations | 1 | 1994 | 82 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2014 | 76 | 0.030 |
Why?
| | Drug Synergism | 2 | 2008 | 357 | 0.030 |
Why?
| | Diprenorphine | 1 | 2013 | 1 | 0.020 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2013 | 15 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 2013 | 24 | 0.020 |
Why?
| | Isotopes | 1 | 2013 | 34 | 0.020 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2013 | 56 | 0.020 |
Why?
| | Protein Binding | 2 | 2013 | 2273 | 0.020 |
Why?
| | Ventral Tegmental Area | 1 | 2012 | 60 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2013 | 276 | 0.020 |
Why?
| | Methylphenidate | 1 | 2012 | 49 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 744 | 0.020 |
Why?
| | Methadone | 1 | 2013 | 121 | 0.020 |
Why?
| | Concanavalin A | 1 | 2010 | 71 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2000 | 1094 | 0.020 |
Why?
| | Spinal Cord | 1 | 2013 | 380 | 0.020 |
Why?
| | Pharmaceutical Vehicles | 1 | 2008 | 12 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2010 | 329 | 0.020 |
Why?
| | Catheterization | 1 | 2009 | 183 | 0.020 |
Why?
| | Receptors, GABA | 2 | 1997 | 13 | 0.020 |
Why?
| | Potassium | 2 | 1997 | 152 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 372 | 0.010 |
Why?
| | Aged | 1 | 2025 | 25913 | 0.010 |
Why?
| | Middle Aged | 2 | 2025 | 35875 | 0.010 |
Why?
| | Receptors, Somatostatin | 1 | 2004 | 23 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 721 | 0.010 |
Why?
| | Peptides | 1 | 2010 | 995 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2608 | 0.010 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2002 | 6 | 0.010 |
Why?
| | LIM Domain Proteins | 1 | 2002 | 21 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 2004 | 275 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2002 | 59 | 0.010 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2002 | 62 | 0.010 |
Why?
| | Symporters | 1 | 2002 | 48 | 0.010 |
Why?
| | Mutation | 1 | 2013 | 4089 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 940 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 862 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2002 | 459 | 0.010 |
Why?
| | Pentazocine | 1 | 1998 | 1 | 0.010 |
Why?
| | Guanidines | 1 | 1998 | 41 | 0.010 |
Why?
| | Dextromethorphan | 1 | 1998 | 23 | 0.010 |
Why?
| | Haloperidol | 1 | 1998 | 33 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1998 | 193 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 11679 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 1997 | 79 | 0.010 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 1997 | 17 | 0.010 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 1997 | 74 | 0.010 |
Why?
| | Potassium Channel Blockers | 1 | 1997 | 47 | 0.010 |
Why?
| | Phospholipases A | 1 | 1997 | 98 | 0.010 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1997 | 6 | 0.010 |
Why?
| | Receptors, Presynaptic | 1 | 1997 | 9 | 0.010 |
Why?
| | Tetrodotoxin | 1 | 1997 | 40 | 0.010 |
Why?
| | Cell Line | 1 | 2002 | 2882 | 0.010 |
Why?
| | Ligands | 1 | 1998 | 673 | 0.010 |
Why?
| | Neurofibromatoses | 1 | 1996 | 8 | 0.010 |
Why?
| | Anticonvulsants | 1 | 1998 | 235 | 0.010 |
Why?
| | Cell Size | 1 | 1996 | 92 | 0.010 |
Why?
| | Neural Conduction | 1 | 1996 | 92 | 0.010 |
Why?
| | Back Pain | 1 | 1996 | 52 | 0.010 |
Why?
| | Binding Sites | 1 | 1998 | 1329 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1996 | 561 | 0.010 |
Why?
| | Aspirin | 1 | 1997 | 399 | 0.010 |
Why?
| | Kidney | 1 | 2002 | 1495 | 0.010 |
Why?
| | Neuralgia | 1 | 1996 | 144 | 0.010 |
Why?
| | Scoliosis | 1 | 1996 | 223 | 0.010 |
Why?
| | Adult | 1 | 1996 | 40449 | 0.000 |
Why?
|
|
Ingram's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|